CL2015003444A1 - Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo - Google Patents
Compuestos de 3,4 dihidroisoquinolin-2(1h)-iloInfo
- Publication number
- CL2015003444A1 CL2015003444A1 CL2015003444A CL2015003444A CL2015003444A1 CL 2015003444 A1 CL2015003444 A1 CL 2015003444A1 CL 2015003444 A CL2015003444 A CL 2015003444A CL 2015003444 A CL2015003444 A CL 2015003444A CL 2015003444 A1 CL2015003444 A1 CL 2015003444A1
- Authority
- CL
- Chile
- Prior art keywords
- dihydroisoquinolin
- compounds
- treatment
- ilo
- schizophrenia
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- -1 3,4 dihydroisoquinolin-2 (1h) -yl Chemical group 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
COMPUESTOS DERIVADOS DE 3,4 DIHIDROISOQUINOLIN-2(1H)-ILO; COMPOSICION FARMACEUTICA; Y SU USO EN EL TRATAMIENTO DE LA ESQUIZOFRENIA Y EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361828740P | 2013-05-30 | 2013-05-30 | |
| US201361905329P | 2013-11-18 | 2013-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015003444A1 true CL2015003444A1 (es) | 2016-07-15 |
Family
ID=50983199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015003444A CL2015003444A1 (es) | 2013-05-30 | 2015-11-24 | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8962654B2 (es) |
| EP (1) | EP3004061B8 (es) |
| JP (2) | JP6130590B2 (es) |
| KR (1) | KR101808933B1 (es) |
| CN (1) | CN105228985B (es) |
| AP (1) | AP2015008867A0 (es) |
| AU (2) | AU2014274435B2 (es) |
| BR (1) | BR112015029090B1 (es) |
| CA (1) | CA2912849C (es) |
| CL (1) | CL2015003444A1 (es) |
| CR (1) | CR20150622A (es) |
| CY (1) | CY1119361T1 (es) |
| DK (1) | DK3004061T3 (es) |
| DO (1) | DOP2015000289A (es) |
| EA (1) | EA029220B1 (es) |
| ES (1) | ES2647086T3 (es) |
| GT (1) | GT201500334A (es) |
| HK (1) | HK1216314A1 (es) |
| HR (1) | HRP20171696T1 (es) |
| HU (1) | HUE034607T2 (es) |
| JO (1) | JO3316B1 (es) |
| LT (1) | LT3004061T (es) |
| ME (1) | ME02838B (es) |
| MX (1) | MX373843B (es) |
| MY (1) | MY180751A (es) |
| NZ (1) | NZ713809A (es) |
| PE (1) | PE20152032A1 (es) |
| PH (1) | PH12015502658B1 (es) |
| PL (1) | PL3004061T3 (es) |
| PT (1) | PT3004061T (es) |
| RS (1) | RS56294B1 (es) |
| SG (1) | SG11201509310QA (es) |
| SI (1) | SI3004061T1 (es) |
| TN (1) | TN2015000514A1 (es) |
| TW (2) | TWI691489B (es) |
| UA (1) | UA118759C2 (es) |
| WO (1) | WO2014193781A1 (es) |
| ZA (1) | ZA201508213B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2504332T2 (sl) | 2009-11-27 | 2021-08-31 | Genzyme Corporation | Amorfna in kristalinična oblika GENZ 112638 hemitartrata kot inhibitor glukozilceramid sintaze |
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| AR106332A1 (es) * | 2015-10-23 | 2018-01-03 | Lilly Co Eli | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona |
| BR112018070363A2 (pt) * | 2016-04-13 | 2019-01-29 | Ucb Biopharma Sprl | derivados de tetraidroisoquinolina |
| IL292923B2 (en) | 2017-02-21 | 2024-05-01 | Univ Emory | CXCR4 cytokine receptor modulators and related uses |
| EP3418270A1 (en) | 2017-06-19 | 2018-12-26 | Universidad Complutense De Madrid | Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor |
| WO2019105913A1 (en) | 2017-12-01 | 2019-06-06 | Ucb Biopharma Sprl | Imaging agents |
| TWI725408B (zh) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
| EP4417258A3 (en) | 2018-12-18 | 2024-10-30 | Eli Lilly and Company | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
| TWI843678B (zh) | 2019-06-18 | 2024-05-21 | 美商美國禮來大藥廠 | 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物 |
| WO2021001286A1 (en) | 2019-07-01 | 2021-01-07 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| CA3139571A1 (en) * | 2019-07-01 | 2021-01-07 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| LT4200280T (lt) | 2020-10-07 | 2024-04-25 | Eli Lilly And Company | Fenil-3,4-dihidroizochinolin-2(1h)-il-etan-1-ono dariniai kaip pozityvūs alosteriniai dopamino d1 receptoriaus moduliatoriai |
| CA3198635A1 (en) | 2020-12-03 | 2022-06-09 | UCB Biopharma SRL | Octahydroisoquinolinyl derivatives |
| CA3203281A1 (en) * | 2020-12-18 | 2022-06-23 | UCB Biopharma SRL | Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone |
| EP4263522B1 (en) * | 2020-12-18 | 2024-10-02 | UCB Biopharma SRL | Dihydroisoquinolinyl derivatives |
| LT4263517T (lt) | 2020-12-18 | 2025-01-10 | UCB Biopharma SRL | Pakeistasis tetrahidroizochinolino darinys kaip d1 teigiamas alosterinis moduliatorius |
| EP4262756A1 (en) * | 2020-12-18 | 2023-10-25 | UCB Biopharma SRL | Amorphous solid dispersions |
| WO2022192231A1 (en) | 2021-03-08 | 2022-09-15 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis |
| CN117337173A (zh) | 2021-03-09 | 2024-01-02 | 伊莱利利公司 | 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE97893T1 (de) | 1988-02-19 | 1993-12-15 | Smithkline Beecham Farma | 1,2,3,4-tetrahydroisoquinoline, verfharen zu ihrer herstellung und ihre verwendung als kappa- rezeptor agonisten. |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| US5932590A (en) | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| NZ506251A (en) | 1998-02-18 | 2003-01-31 | Neurosearch As | Benzothiadiazine and benzothiadiazepine derivatives and their use as positive AMPA receptor modulators |
| DE60115227T2 (de) | 2000-05-11 | 2006-08-24 | Bristol-Myers Squibb Co. | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| US7601739B2 (en) | 2003-08-08 | 2009-10-13 | Virgina Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases |
| US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| EP2125741A1 (en) * | 2007-03-01 | 2009-12-02 | Janssen Pharmaceutica, N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
| US20120252853A1 (en) | 2011-04-01 | 2012-10-04 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
| US9255090B2 (en) | 2011-12-21 | 2016-02-09 | Actelion Pharmaceuticals Ltd. | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
-
2014
- 2014-05-15 JO JOP/2014/0163A patent/JO3316B1/ar active
- 2014-05-16 TW TW108104751A patent/TWI691489B/zh active
- 2014-05-16 TW TW103117402A patent/TWI691488B/zh active
- 2014-05-27 EP EP14732756.3A patent/EP3004061B8/en active Active
- 2014-05-27 HU HUE14732756A patent/HUE034607T2/en unknown
- 2014-05-27 PE PE2015002534A patent/PE20152032A1/es unknown
- 2014-05-27 PT PT147327563T patent/PT3004061T/pt unknown
- 2014-05-27 MY MYPI2015704341A patent/MY180751A/en unknown
- 2014-05-27 CA CA2912849A patent/CA2912849C/en active Active
- 2014-05-27 PL PL14732756T patent/PL3004061T3/pl unknown
- 2014-05-27 RS RS20170896A patent/RS56294B1/sr unknown
- 2014-05-27 AU AU2014274435A patent/AU2014274435B2/en active Active
- 2014-05-27 LT LTEP14732756.3T patent/LT3004061T/lt unknown
- 2014-05-27 DK DK14732756.3T patent/DK3004061T3/en active
- 2014-05-27 CN CN201480031030.7A patent/CN105228985B/zh active Active
- 2014-05-27 BR BR112015029090-6A patent/BR112015029090B1/pt active IP Right Grant
- 2014-05-27 WO PCT/US2014/039494 patent/WO2014193781A1/en active Application Filing
- 2014-05-27 MX MX2015016495A patent/MX373843B/es active IP Right Grant
- 2014-05-27 KR KR1020157033616A patent/KR101808933B1/ko active Active
- 2014-05-27 TN TN2015000514A patent/TN2015000514A1/en unknown
- 2014-05-27 US US14/287,239 patent/US8962654B2/en active Active
- 2014-05-27 SG SG11201509310QA patent/SG11201509310QA/en unknown
- 2014-05-27 ME MEP-2017-221A patent/ME02838B/me unknown
- 2014-05-27 ES ES14732756.3T patent/ES2647086T3/es active Active
- 2014-05-27 SI SI201430377T patent/SI3004061T1/sl unknown
- 2014-05-27 NZ NZ71380914A patent/NZ713809A/en unknown
- 2014-05-27 EA EA201592082A patent/EA029220B1/ru not_active IP Right Cessation
- 2014-05-27 UA UAA201511029A patent/UA118759C2/uk unknown
- 2014-05-27 JP JP2016516713A patent/JP6130590B2/ja active Active
- 2014-05-27 AP AP2015008867A patent/AP2015008867A0/xx unknown
-
2015
- 2015-11-06 ZA ZA2015/08213A patent/ZA201508213B/en unknown
- 2015-11-23 CR CR20150622A patent/CR20150622A/es unknown
- 2015-11-24 CL CL2015003444A patent/CL2015003444A1/es unknown
- 2015-11-26 GT GT201500334A patent/GT201500334A/es unknown
- 2015-11-27 PH PH12015502658A patent/PH12015502658B1/en unknown
- 2015-11-27 DO DO2015000289A patent/DOP2015000289A/es unknown
-
2016
- 2016-04-14 HK HK16104287.6A patent/HK1216314A1/zh unknown
- 2016-10-07 AU AU2016238934A patent/AU2016238934B2/en active Active
-
2017
- 2017-04-13 JP JP2017079775A patent/JP6387433B2/ja active Active
- 2017-10-05 CY CY20171101039T patent/CY1119361T1/el unknown
- 2017-11-06 HR HRP20171696TT patent/HRP20171696T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
| CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2016001895A1 (es) | Compuestos | |
| CL2016001629A1 (es) | Compuestos tricíclicos como agentes anticancerígenos | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| MX386935B (es) | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| MX392130B (es) | Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2015001702A1 (es) | Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c. | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| CL2013002125A1 (es) | Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia. | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX2021000007A (es) | Formulaciones de enzalutamida. | |
| CL2014002412A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras. | |
| CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| MX382599B (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina. | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| CL2015000784A1 (es) | Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades. | |
| CL2018001171A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer |